JORDAN LASHEA MAYBERRY PA
Prescription History 1982940466
Physician Assistant in Dallas, TX
Quality Rating: 74.59 out of 100 score
NPI Status: Active since January 02, 2013
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JORDAN LASHEA MAYBERRY PA, an active Physician Assistant specialist practicing in Dallas, TX. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 66 documented patient claims. Among these therapy options, the most frequently utilized medication is Epclusa, which accounts for 35 claims alone.
Epclusa
Generic Formulation: Sofosbuvir/VelpatasvirSpecialty: Physician AssistantProvider Avg Cost Per Claim
$26,777.42
State Avg Cost Per Claim
$26,359.23
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice safer sex (including the use of latex condoms) to lower the risk of passing the virus to others.
Mavyret
Generic Formulation: Glecaprevir/PibrentasvirSpecialty: Physician AssistantProvider Avg Cost Per Claim
$14,084.79
State Avg Cost Per Claim
$14,299.57
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is a combination of glecaprevir and pibrentasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Glecaprevir and pibrentasvir work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis) or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice safer sex (such as the use of latex condoms) to lower the risk of passing the virus to others.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JORDAN LASHEA MAYBERRY PA provides transparency into local medical care patterns within Dallas, TX.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
